GLI2 (GLI Family Zinc Finger 2)

This assay enables manufacturers and regulators to meet the growing demand for reliable impurity screening assays that support the characterization of vaccines activating the NF-κB pathway. Future studies must further characterise NF-κB activation by individual TLRs across a broader range of vaccines.

Our studies uncover the developmental origins and molecular mechanisms underlying GLI2-amplified SHH-MB. We also reveal that the MAPK pathway plays a critical role in GLI2-driven SHH-MB tumorigenesis and progression.

P3, N=225, Recruiting, Children's Oncology Group | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2027 --> Dec 2029

Pharmacological inhibition of the CXCR1/2 axis with reparixin effectively blocked OCM-mediated induction of both NFIX and FRY, suggesting that chemokine signaling initiates this pro-invasive loop. Collectively, these findings suggest that FRY is a macrophage-driven mediator of invasion and underscore its potential relevance in ovarian cancer.

Results show that the peel from Opuntia fruits, a waste byproduct of little value so far, is a source of bioactive compounds with health-promoting properties. This may represent a revalorization of Opuntia crops and wild species that grow in arid and semiarid regions.

The breakpoint was identical to those in the previously reported cases. Taken together, these findings suggest that PTCH1::GLI2 fusion may define a distinctive subtype of gastric mesenchymal tumors within the GLI1/GLI2-altered spectrum.

Functionally, while adducted mRNAs exhibited poor capacity for protein expression in cultured human 293T cells, they did not stimulate significant gene expression involved in innate immunity for RNA sensing and downstream type I interferon pathway activation in human THP1 cells. These findings not only clarify important functional consequences of adducted mRNAs, but also establish impurity control and thermal management as actionable strategies for advancing mRNA therapeutics.

This resulted in the production of two new sarocladone analogues, collecladones A (7) and B (8), lacking the C-2-C-3 double bond present in the sarocladones. These findings establish HR-PKS-T3PKS collaboration as an underexplored source of fungal chemical diversity.

Pharmacokinetic profiling demonstrated favorable plasma exposure and metabolic stability, with an oral half-life (T1/2) of 9.92 h. These integrated preclinical studies establish X41 as a structurally novel oral STING agonist with significant translational potential, positioning it as a promising candidate for the immunotherapy of solid tumors.

Profiling inflammatory mediators revealed significant modulation upon treatment with SMO inhibitors, possibly affecting chemotactic and immune functions. Collectively, these findings provide deeper insight into the role of the Hh pathway in melanoma and support the potential repurposing of Hh inhibitors as therapeutic agents for melanoma.

Taken together, our findings reveal that aging affects tumor-associated vasculature but not BCC formation or regression in our model. These results are in keeping with the notion that a major contributor to the increased incidence of BCCs in elderly patients is the accumulation of oncogenic driver mutations over time rather than intrinsic changes in aged skin that promote BCC tumorigenesis.

These findings reveal novel perspectives on the natural compound Ecliptasaponin A, demonstrating its dual-targeting capability against both NLRP3 inflammasome activation and YAP signaling cascades. This discovery highlights its potential as a promising therapeutic agent for mitigating MASH.